Trubion Drug Kills Cancer in Blood
Trubion Pharmaceuticals (NASDAQ: TRBN), a Seattle-based developer of targeted therapies, said today that its experimental TRU-016 treatment showed encouraging results in a small trial of 26 patients with chronic lymphocytic leukemia. The drug reduced the median number of cancer cells circulating in the blood by about two-thirds, researchers said. Researchers have not yet pinpointed a maximum tolerated dose. Detailed data was presented at the American Society of Clinical Oncology meeting in Orlando, FL.